For HER2-positive gastric cancer, the KEYNOTE-811 study showed that pembrolizumab in combination with trastuzumab and chemotherapy could improve the objective response rate (ORR) to 74.4% in patients with HER-2-positive advanced gastric cancer. Here, ERBB2 is linked to gastric cancer.